B7H3 is overexpressed in prostate cancer compared with benign prostatic hyperplasia, and high B7H3 expression is positively correlated with adenocarcinoma aggressiveness, observed as overexpression in metastatic and castration-resistant disease (7–9). Here, CD276 is linked to prostate carcinoma.